We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




LAMP Malaria Test Detects Less-Diagnosed Species

By LabMedica International staff writers
Posted on 16 May 2019
A new loop-mediated isothermal amplification (LAMP) molecular assay has been developed that can detect Plasmodium vivax, a species of the parasite that causes malaria.

Almost all molecular tests currently available detect P. More...
falciparum, in part because it causes the highest mortality of the different species. However, P. vivax is actually more widespread, with more than 2.5 billion people at risk of infection.

The new LAMP assay was evaluated recently in Colombia using a protocol of consecutive testing, a pan-plasmodium LAMP test followed by the P. vivax test, with polymerase chain reaction (PCR)-based testing as the comparator. In all, 365 fingerpick blood samples from patients with fever were evaluated, and the P. vivax test showed a sensitivity of approximately 94% and a specificity of 92%. Importantly, the test also has a low limit of detection of around one to two parasites per microliter of patient sample.

The LAMP assay was developed by Eiken Chemical (Tokyo, Japan) with the collaboration of The Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) who coordinated laboratory testing in collaboration with the Hospital for Tropical Diseases (London, UK). FIND has negotiated pricing for the Loopamp tests and HumaTurb system, with a kit of 96 P. vivax tests costing EUR 499.20 (USD 560) and the HumaTurb costing EUR 15,900. There is also a solution for lower-throughput settings called HumaLoop that is a lower cost.

Xavier C. Ding, PhD, the team leader for malaria diagnostics at FIND, said, “It's only recently that there is a recognition that if we are ever to eliminate malaria, we also need some vivax-specific tests, because that species has its own biological specificities and is much more challenging to eliminate that falciparum.” This is because, unlike P. falciparum, P. vivax can lie dormant in the liver of an infected person in a stage called a hypnozoite, and a person with hypnozoites is then prone to relapsing malarial disease. Dr. Ding added, “There is big hope that this will make it easier and more accessible to get treatment for liver-stage parasites, but that also means you also need good diagnostic tools to identify those people who have vivax.”

Related Links:
Eiken Chemical
The Foundation for Innovative New Diagnostics
Hospital for Tropical Diseases


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.